



San Diego, CA

June 13-16, 2022

ALBERTA @

2022

BIO INTERNATIONAL

www.bioalberta.com

ALBERTA AT A GLANCE

Alberta quick facts

- Alberta's life sciences are a thriving sector responsible for over \$1.0 billion in revenues and expected to employ over 15,000 Albertans in 2021.
- Of Alberta's 650 life sciences companies 90 % are located in Calgary (50.2%) and Edmonton (40.5%).
- The University of Alberta has ranked in the top 3 globally for Artificial Intelligence for the past 25 years.
- Single integrated health system under Alberta Health Services (AHS)

Competitive taxes

- Albertans pay the lowest overall taxes in Canada.
- We have a competitive tax system with low personal and corporate income tax rates, no payroll tax, no provincial sales tax and no health premiums.

A skilled and productive workforce

- Alberta's labour force consists of more than 2.1 million workers aged 15 and up. Approximately 1.5 million workers are aged 25 and up and have received post-secondary education.

Clinical Trials Excellence

- Alberta has over 850 principal investigators and over 1400 clinical trials in progress
- 24% of current Canadian clinical trials are being conducted in Alberta

Top therapeutic areas by rank:

1. Cancer
2. Nervous System
3. Cardiology
4. Digestive Health

5. Blood & Lymph Disorders
6. Nutrition & Metabolic
7. Immune System
8. Mental Health

CONTENTS

- | | | | | | |
|----------|---|-----------|---|-----------|--|
| 2 | Alberta at a Glance | 10 | Edmonton Global | 16 | Nanostics |
| 4 | BioAlberta | 11 | Chem Routes | 17 | Syantra |
| 5 | Invest Alberta | 12 | Entos | 18 | Xortx |
| 6 | 48 Hour Discovery | 13 | GlycoNet | 19 | University
Hospital
Foundation |
| 7 | Applied
Pharmaceutical
Innovation | 14 | Health Cities | 20 | Alberta Real World
Evidence
Consortium |
| 8 | Biohubx | 15 | La Ka Shing
Institute of
Virology | | |
| 9 | Calgary Economic
Development | | | | |

BioAlberta

BioAlberta is a private, not-for-profit industry association representing the growing life sciences sector in the province. Our vision is to build a thriving and globally competitive life sciences industry that fuels key sectors of Alberta's economy. The organization serves as a central voice and organizing hub and champion for the industry, providing leadership through focused activities that promote and enable sector development in Alberta. BioAlberta activities are focused in three key strategic areas:

- Advocacy
- Industry development
- Promotion, marketing and networking

BUSINESS OBJECTIVES

Promote Alberta's life sciences sector and its companies to attract investments and partnerships. Secondary to this, BioAlberta is looking to connect with potential companies looking to invest in Alberta, mentors and accelerator programs.

CONTACT

Robb Stoddard, President and CEO

robb@bioalberta.com

+1-587- 597-7622

www.bioalberta.com



Invest Alberta

Invest Alberta Corporation (IAC) works directly with investors globally to start up or scale up in Alberta, Canada. With offices in Calgary, Edmonton, along with 11 international offices located in key markets around the world, we connect industry, government partners, and economic development organizations and offer seamless services that make it easy for investment to flow into the province. With a strong entrepreneurial culture, we are taking new and innovative approaches to expediate the process of doing new business in Alberta.

BUSINESS OBJECTIVES

In Alberta, we've always challenged the status quo with innovative ways to do business, from earlier-maturing wheat at the turn of the 19th century to today's cutting-edge AI research. Our relentless pursuit of new ideas is why many global brands have already located their offices in Alberta and why our universities work closely with research institutions from all around the world.

CONTACT

Lynette Tremblay, COO
lynette.tremblay@investalberta.ca

www.investalberta.ca



48 Hour Discovery

Founded in 2017, 48Hour Discovery (48HD) is a revenue stage University of Alberta spin-off headquartered in Edmonton, Alberta. 48HD combines genetically encoded macrocycle libraries, based on unique chemical scaffolds and proprietary algorithms to screen billion-scale libraries of peptide sequences for early-stage drug candidates. The integrated approach to molecular discovery generates drug discovery leads at a fraction of the cost and time when compared to current molecular screening enterprises.

BUSINESS OBJECTIVES

48HD seeks collaboration with pharmaceutical companies interested in the use of the 48HD platform for generating new drug leads.

CONTACT

Martin Truksa, PhD, MBA Vice President, R&D
mtruksa@48hourdiscovery.com



Applied Pharmaceutical Innovation

API is a not-for-profit organization with an expert interdisciplinary team that works with a network of collaborating organizations. As a whole, we provide the expertise, services, and infrastructure of a pharmaceutical company. We help innovators launch their ideas into the real world, connect industry to the services they need for commercial success, and accelerate all aspects of the drug development process.

BUSINESS OBJECTIVES

- Provide industry with opportunities to access world-class expertise and services.
- Support researchers and startups to create a viable path forward.
- Train and empower post-doctoral fellows and students.

CONTACT

Andrew MacIsaac, Director & CEO
andrew.macisaac@appliedpharma.ca

Hana Marinkovic, Director, Corporate Affairs
hana.marinkovic@appliedpharma.ca

www.appliedpharma.ca



Biohubx

Biohubx is an industry-facing not-for-profit organization that supports life science companies as they commercialize, scale and grow. We provide technical services, quality and regulatory support, private and shared laboratory and office space and access to many opportunities and resources in Canada.

BUSINESS OBJECTIVES

- Supporting companies interested in expanding to the North American or Canadian market
- Connecting with companies in the medical device, sensor, mobility, imaging, or pediatric space
- To learn of global opportunities for Biohubx companies

CONTACT

Elisa Park Kim, Director of Business Development
elisa@biohubx.com
www.linkedin.com/in/elisa-park-kim

Calgary Economic Development

Calgary Economic Development is a not-for-profit corporation funded by the City of Calgary, community partners, other orders of government and the private sector. We work with business, government and community partners to position Calgary as the location of choice for the purpose of attracting business attraction & investment, fostering trade and developing Calgary's workforce.

BUSINESS OBJECTIVES

Interested in companies who have a desire to learn more about investment opportunities in Calgary or have questions about doing business, expanding or relocating to Alberta. Life sciences

CONTACT

Lin Tang, Business Development Manager, Life Sciences
ltang@calgaryeconomicdevelopment.com

www.calgaryeconomicdevelopment.com



Edmonton Global

The purpose of Edmonton Global is to radically transform and grow the economy of the Edmonton Metropolitan Region.

Our work promotes the region globally and we're focused on attracting and retaining business investment and trade right here.

We are the first ever regional economic development corporation in the region, working to create local, regional, provincial, national, and global partnerships. We collaborate with all levels of government and economic development agencies including our 14 municipalities, Invest Alberta, Alberta's Industrial Heartland Association, the Edmonton International Airport, Edmonton Health City, the Alberta Machine Intelligence Institute, and Invest in Canada.

BUSINESS OBJECTIVES

Edmonton Global's vision is to make the Edmonton Metropolitan Region the choice location for global investment. To attract investment and quality jobs to the region, our strategy is to strengthen and support growth, innovation, and competitiveness — all in collaboration with the region's 14 municipalities.

As a foreign direct investment (FDI) and international business development company, we work as an ally to attract investment to, and promote trade from, Canada and our region. We're ready to connect with you and support your work.

CONTACT

Robert Sikora, Senior Manager, Business Development of Trade and Investment
rsikora@edmontonglobal.ca

www.edmontonglobal.ca



ChemRoutes

Chem Routes

ChemRoutes Corporation is a private drug discovery technology provider operating at the interface of organic chemistry, chemical biology, drug discovery and nanotechnology. It was established in 1999 and is headquartered in Edmonton, Alberta, Canada.

ChemRoutes Corporation has a thorough understanding of the drug discovery and development process, and an experienced scientific advisory board. We focus on early stage drug discovery to pre-clinical research. Our proprietary and novel small molecule based scaffolds, building blocks, templates, chemical arrays and new chemical target research spans infectious, neurodegenerative and metabolic diseases, pain, inflammation and oncology. We have consistently delivered results, leading to global partnerships with over 80 pharmaceutical, agrochemical and biotech companies accessing our novel chemistry driven platforms for new molecular targets and biochemical pathways

BUSINESS OBJECTIVES

- Pursue integrity and reliability
- Follow good business practices
- Adapt to future trends and needs quickly
- Collaborate effectively to achieve superior solutions
- Deliver products with appropriate costs, speed and quality
- Create value for our stakeholders
- Be accountable for our actions and their results

CONTACT

www.chemroutes.com



Entos

A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. With our partners, such as Eli Lilly and BioMarin, we are developing next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of mRNA or DNA into target cells through direct fusion. For more information, visit www.entospharma.com

BUSINESS OBJECTIVES

Network with investors, industry, and Canadian government officials to promote Entos and its Fusogenix PLV platform and increase funding for the development and biomanufacturing of Canadian-made genetic medicines and vaccines, including Entos' Covigenix COVID-19 DNA vaccine.

CONTACT

John Lewis, Ph.D. CEO, Entos Pharmaceuticals
info@entospharma.com



GlycoNet

GlycoNet

The Canadian Glycomics Network (GlycoNet) is a research-led, science-backed national leader in the field of glycomics. Our mission is to accelerate enabling technologies and deliver health products in the form of therapeutics, vaccines, and diagnostics.

We have a network of 170+ researchers at institutes from across Canada. Our current funded glycomics projects are in the areas of:

- Oncology (e.g. breast, pancreatic, prostate, pan-cancer)
- Diabetes (e.g. Type I, Type II)
- Other chronic diseases (e.g. inflammatory bowel disease, heart disease, stroke, multiple sclerosis)
- Rare genetic diseases (e.g. San Filippo, Tay-Sachs, muscular dystrophy,
- Neurodegenerative diseases (e.g. Alzheimer's, Parkinson's, Huntington's)
- Antimicrobials and infectious diseases (e.g. viral, fungal, bacterial)
- Enabling technologies (e.g. drug discovery, glycoengineering, cell therapy)

BUSINESS OBJECTIVES

In support of strategic partnerships and venture creation, GlycoNet is targeting additional funding to translational stage research as well as the protection of intellectual property.

GlycoNet's goal is to establish a successful innovation hub in glycomics research and translation through securing partnerships and funding opportunities, commercialization of technologies and creation of spin-off companies.

Company Objectives: Seek partners to accelerate and power our portfolio of translational research via licensing or collaborations

- Seek investors that can fund discovery/preclinical technologies
- Seek early-stage investors for new company creation

CONTACT

Dr. Rui Resendes, Director of Strategic Partnerships

Dr. Elizabeth Nanak, CEO

780-492-6204

www.canadianglycomics.ca



Health Cities

Health Cities is an economic development initiative created to catalyze and accelerate innovation in the health sector of Edmonton.

We work with our innovation ecosystem to leverage Edmonton's tremendous assets – in health, health research, data, artificial intelligence and entrepreneurship – and showcase our region as a premier location to invest in and do health innovation.

We create engines of growth to enable innovators – especially companies – to co-develop, validate, adopt and showcase the capabilities in our region. Our focus is on transforming innovations from our health ecosystem into solutions that have commercial application and global relevance; adopting them for impact in Edmonton and scaling them for export to global markets.

BUSINESS OBJECTIVES

Health Cities role is to broker innovation consortiums, bringing together highly talented people and organizations to enable innovation and products to get to market. Health Cities serves as a central connection point for Edmonton's health innovation sector; working with and seeking inspired partners who share a vision for excellence, have a culture of collaboration and who are driving to take health innovation to the next level.

CONTACT

Reg Joseph, CEO
reg@healthcities.ca

www.healthcities.ca



Li Ka Shing
Institute of Virology

La Ka Shing Institute of Virology

The Li Ka Shing Institute of Virology (LKSIV) unites a consortium of world-renowned researchers to promote scientific advancements aimed at expanding our understanding of viruses and other selected pathogens, their respective disease pathogenesis, and host immune responses to such infections. The institute builds on internationally recognized virology, immunology and other expertise in human diseases, as well as infrastructure with global connections to partners such as the U.S. National Institutes of Health, the Bill and Melinda Gates Foundation, Canadian Institutes of Health Research (CIHR), and more.

BUSINESS OBJECTIVES

Through the Li Ka Shing Applied Virology Institute (LKSIV), the LKSIV further supports discoveries in vaccines, treatments, and diagnostic tests for viral and selected other diseases affecting humans. The LKSIV collaborates with 68 international institutes, agencies, and networks in 23 countries around the world. Most LKSIV members are associated with the Department of Medical Microbiology & Immunology at the University of Alberta, with member affiliation encompassing 18 other units (institutes, departments, and faculties) at the University of Alberta.

CONTACT

Dr. Lorne Tyrrell

ltyrrell@ualberta.ca



Nanostics

Nanostics is a privately held Alberta-based company focused on the development and commercialization of novel, non-invasive diagnostic tests for cancer and other diseases. The technology at the core of Nanostics is an advanced liquid biopsy platform and state of the art machine learning algorithm for accurate diagnoses from a single drop of blood. The technology is applicable to a wide range of diseases including prostate, ovarian, pancreatic cancers, as well as cardiovascular, degenerative and neurological diseases. Nanostics' lead product, ClarityDX Prostate, is the most accurate diagnostic tool for prostate cancer.

BUSINESS OBJECTIVES

Our first goal at the BIO International Convention is to connect with investors and strategic partners to support our ClarityDX Prostate test and clinical studies. Our second goal is to establish additional partners to develop other tests on our platform.

CONTACT

Colin Coros, Chief Commercial Officer

www.nanosticsdx.com



Syantra

Syantra Inc. is a privately held, precision healthcare company that's changing the way diseases are detected and treated.

The company's flagship product, Syantra DX | Breast Cancer, is a screening blood test for the detection of breast cancer. It measures a panel of gene expression biomarkers from whole blood and then uses a software package, developed with machine learning, to interpret data and provide a result of positive or negative.

Syantra DX | Breast Cancer represents an early entrant into the emerging molecular diagnostic sector.

BUSINESS OBJECTIVES

Clinical studies for Syantra DX | Breast Cancer are ongoing through Identify Breast Cancer (IDBC) sites in Canada, the UK and South Korea. US site studies are not currently recruiting.

Syantra Inc. is also working on therapeutics (Syantra RX), utilizing a platform in biomarker and drug discovery that is patented/registered in multiple countries.

CONTACT

Kristina Rinker, PhD, PEng Co-Founder & CSO
tina.rinker@syantra.com

www.syantra.com



Xortx

XORTX Therapeutics, Inc. is a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Our focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2.

We possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury.

BUSINESS OBJECTIVES

Technology development is an integral part of our corporate strategy. XORTX Therapeutics is working with a number of development and technological partners with proven competence in manufacturing, non-clinical and clinical program development. Importantly, contract research organizations with experience in clinical and regulatory development as well as an orphan drug focus. Our common goal is to bring novel therapies to market to address the needs of both patients and physicians.

CONTACT

Alan Davidoff, M.D.
adavidoff@xortx.com

www.xortx.com



**University
Hospital
Foundation**

University Hospital Foundation

The University Hospital Foundation was created in 1962 by an act in the Alberta legislature. In the decades since, we have evolved into one of the most successful hospital fundraising organizations in Canada. We raise funds to advance patient care and innovation at the University of Alberta Hospital, the Mazankowski Alberta Heart Institute and the Kaye Edmonton Clinic.

BUSINESS OBJECTIVES

We are driven to find bold solutions, inspire new ideas, and ignite new discoveries by bringing the right people together and giving them the resources they need to achieve the impossible.

- Our hospitals provide patients with the latest in diagnostic imaging and treatment
- We support breakthrough research that brings discoveries to the bedside

CONTACT

www.givetouhf.ca



Alberta Real World Evidence Consortium

The Alberta Real World Evidence Consortium conducts rigorous, high-quality decision-grade real world evidence research studies that engage key stakeholders to answer questions that are relevant to providers, decision makers, clinicians, patients, and industry in a customer focused and timely manner. The Consortium is composed of a provincial team of established academic and clinical research leaders, methodological and analytical experts, project managers, and research administrators from the Universities of Alberta and Calgary, and the Institute of Health Economics.

The Consortium is uniquely positioned within Alberta, Canada, which has one of the largest, most mature, detailed, and comprehensive health system data repositories in Canada. With this advantage, Alberta is poised to become a global leader in real world evidence generation. The Consortium conducts basic to highly complex real world evidence research studies, generating a wide range of evidence such as burden of illness, pharmacoepidemiological, treatment patterns, and drug safety and effectiveness. Alberta also has distinct advantages that make the province attractive to life sciences-related activities including a single health authority and the largest fully integrated health system in Canada, Strategic Clinical Networks to drive innovation and its implementation across the health system, and an advanced and comprehensive provincial electronic medical record.

BUSINESS OBJECTIVES

Partnering, research collaborations, business development/attraction of investment in real world evidence research studies.

CONTACT

Karen Martins, Project Lead, The Alberta Real World Evidence Consortium
Email: martinuk@ualberta.ca

www.albertarwe.ca

NOTES

NOTES

NOTES

